This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Vesselle, H. Articles by Wood, D. E. Search for Related Content PubMed PubMed Citation Articles by Vesselle, H. Articles by Wood, D. E.

Relationship between Non-Small Cell Lung Cancer Fluorodeoxyglucose Uptake at Positron Emission Tomography and Surgical Stage with Relevance to Patient Prognosis

Departments of ¹ Radiology, ² Pathology, and ³ Surgery, Division of Thoracic Surgery, University of Washington, Seattle, Washington

Purpose: Because the tumor stage is the most significant prognostic factor for non-small cell lung cancer (NSCLC) and given that NSCLC [¹⁸F]fluorodeoxyglucose (¹⁸F-FDG) uptake appears to have prognostic significance, we examined the relationship between NSCLC ¹⁸F-FDG uptake and surgical stage.

Experimental Design: One hundred seventy-eight patients with a proven diagnosis of NSCLC were enrolled, then imaged with ¹⁸F-FDG positron emission tomography and their disease thoroughly staged. Primary tumor size at computed tomography and ¹⁸F-FDG uptake were compared to overall tumor stage and to T, N, and M stage descriptors. Tumor uptake was quantitated by maximum pixel-standardized uptake value (maxSUV) and then partial volume corrected for lesion size using recovery coefficients.

Results: A significant difference in tumor size was associated with tumors of different TNM stage, T status, N status, or M status. Similarly, the primary tumor maxSUV was significantly associated with TNM stage, T status, and M status. However, we observed no significant difference in the partial-volume-corrected tumor maxSUV for different stages; different T, N, or M descriptors; tumors without evidence of spread (N₀M₀) versus tumors with nodal spread (N_1,2,3M₀); or tumors without spread (N₀M₀) versus all others.

Conclusions: We found an association between tumor stage and ¹⁸F-FDG maxSUV, but this relationship disappeared after correction of tumor uptake for lesion size. Therefore, if partial-volume-corrected ¹⁸F-FDG uptake is prognostic of NSCLC outcome, it is not on the basis of a relationship with tumor stage but through a different mechanism.

This article has been cited by other articles:

				Q. Feng, S. E. Hawes, J. E. Stern, L. Wiens, H. Lu, Z. M. Dong, C. D. Jordan, N. B. Kiviat, and H. Vesselle DNA Methylation in Tumor and Matched Normal Tissues from Non-Small Cell Lung Cancer Patients Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 645 - 654. [Abstract] [Full Text] [PDF]

				B. E. Lee, J. Redwine, C. Foster, E. Abella, T. Lown, D. Lau, and D. Follette Mediastinoscopy might not be necessary in patients with non-small cell lung cancer with mediastinal lymph nodes having a maximum standardized uptake value of less than 5.3 J. Thorac. Cardiovasc. Surg., March 1, 2008; 135(3): 615 - 619. [Abstract] [Full Text] [PDF]

				R. J. Downey, T. Akhurst, M. Gonen, B. Park, and V. Rusch Fluorine-18 fluorodeoxyglucose positron emission tomographic maximal standardized uptake value predicts survival independent of clinical but not pathologic TNM staging of resected non-small cell lung cancer J. Thorac. Cardiovasc. Surg., June 1, 2007; 133(6): 1419 - 1427. [Abstract] [Full Text] [PDF]

				M. Soret, S. L. Bacharach, and I. Buvat Partial-Volume Effect in PET Tumor Imaging J. Nucl. Med., June 1, 2007; 48(6): 932 - 945. [Abstract] [Full Text] [PDF]

				H. Vesselle, J. D. Freeman, L. Wiens, J. Stern, H. Q. Nguyen, S. E. Hawes, P. Bastian, A. Salskov, E. Vallieres, and D. E. Wood Fluorodeoxyglucose Uptake of Primary Non-Small Cell Lung Cancer at Positron Emission Tomography: New Contrary Data on Prognostic Role Clin. Cancer Res., June 1, 2007; 13(11): 3255 - 3263. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]